NQO1 and myeloid sarcoma: Furthermore, the application of dimethyl fumarate, an antioxidant medicament and Nrf2 inducer approved for the treatment of MS, resulted in a higher expression of the NQO1 in various in vitro and in vivo experimental models [163, 164].